Hea-Shin Kang, MD
Internal Medicine · Flushing, NYNPI 1528013091
Payments from drug & device makers
Across 522 payments — averaging $19.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$1K
- Takeda Pharmaceuticals U.S.A., Inc.$929
- Novo Nordisk$900
- Amarin Pharma, Inc.$820
- Ardelyx, Inc.$734
- plus $4K from 26 others
What the payments were for
- Food & beverage$10,020100%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 112 | $1,739 |
| AstraZeneca | 58 | $1,130 |
| Takeda Pharmaceuticals U.S.A., Inc. | 54 | $929 |
| Novo Nordisk | 44 | $900 |
| Amarin Pharma, Inc. | 35 | $820 |
| Ardelyx, Inc. | 37 | $734 |
| Amgen | 35 | $696 |
| Axsome Therapeutics, Inc. | 15 | $421 |
| Lilly USA, LLC | 18 | $362 |
| Sumitomo Pharma America, Inc. | 16 | $358 |
| Nestle Healthcare Nutrition Inc. | 14 | $245 |
| Merck | 13 | $232 |
| Boehringer Ingelheim | 11 | $224 |
| Aimmune Therapeutics, Inc. | 9 | $188 |
| Phathom Pharmaceuticals, Inc. | 7 | $162 |
| GSK | 8 | $154 |
| Novartis | 7 | $115 |
| Johnson & Johnson | 4 | $94 |
| Astellas Pharma US Inc | 5 | $94 |
| Insmed, Inc. | 1 | $82 |
| Vivus LLC | 4 | $69 |
| Ironwood Pharmaceuticals, Inc | 2 | $44 |
| Sanofi Pasteur Inc. | 2 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $40 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Eisai Inc. | 1 | $27 |
| Lundbeck LLC | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Pfizer | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Medicomp Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,043 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 1,046 | $1,293,907 |
| VascepaIcosapent Ethyl | 2,599 | $1,097,537 |
| Diclofenac Epolamine | 788 | $529,588 |
| FarxigaDapagliflozin Propanediol | 524 | $385,265 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 473 | $373,407 |
| ZenpepLipase/Protease/Amylase | 250 | $354,416 |
| RybelsusSemaglutide | 271 | $335,729 |
| TrintellixVortioxetine Hydrobromide | 533 | $311,913 |
| ProliaDenosumab | 164 | $283,525 |
| JardianceEmpagliflozin | 278 | $229,271 |
| JanuviaSitagliptin Phosphate | 248 | $206,507 |
| OzempicSemaglutide | 175 | $194,292 |
| EliquisApixaban | 210 | $156,046 |
| RestasisCyclosporine | 194 | $131,102 |
| LinzessLinaclotide | 212 | $128,703 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Restasis, Linzess, Synthroid | $1,739 | $1,563,9651,581 claims |
| MerckJanumet Xr, Januvia, Janumet | $232 | $689,142847 claims |
| Novo NordiskRybelsus, Ozempic | $900 | $530,021446 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $1,130 | $414,746574 claims |
| Aimmune Therapeutics, Inc.Zenpep | $188 | $354,416250 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Dexilant | $929 | $334,525596 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Spiriva Respimat | $224 | $289,095354 claims |
| AmgenProlia | $696 | $283,525164 claims |
| PfizerEliquis | $17 | $156,046210 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Anoro Ellipta | $154 | $112,262230 claims |
| Lilly USA, LLCMounjaro, Trulicity | $362 | $97,44781 claims |
| Ardelyx, Inc.Ibsrela | $734 | $95,56652 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Flushing
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.